Back to top

Aclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical Setbacks

Leerink Partners analyst Thomas Smith reiterated a Hold rating on Aclaris Therapeutics (ACRS – Research Report) on February 27 and set a price targ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Aclaris Therapeutics, Inc. (ACRS)